ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455

Its studies are mostly in Neoplasm Metastasis, led by BeOne Medicines.

Furthest: phase 1, since Jan 27, 20251 company-led study, 1 open or runningNext primary completion: Apr 29, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines11 open or runningphase 1since Jan 27, 2025Jan 27, 2025Apr 29, 2028phase 1 · NCT06803680

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 27, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06803680 · 90 planned · United States, Australia, China

Ahead

  1. Apr 29, 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT06803680

TargetBeta

CD3E →CLDN6 →read by rule
“A bispecific antibody targeting both the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-CLDN6/CD3 Bispecific Antibody XmAb541ruleXencorphase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06803680Neoplasm Metastasis · United States, Australia, China1RecruitingApr 29, 202890

How it is read

Names in the registry

  • “BGB-B455”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.